Your browser doesn't support javascript.
loading
Treatment of metastatic colorectal cancer: focus on panitumumab.
Tay, Rebecca Y; Wong, Rachel; Hawkes, Eliza A.
Afiliação
  • Tay RY; Department of Medical Oncology, Eastern Health, Box Hill, VIC, Australia.
  • Wong R; Department of Medical Oncology, Eastern Health, Box Hill, VIC, Australia ; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia ; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
  • Hawkes EA; Department of Medical Oncology, Eastern Health, Box Hill, VIC, Australia ; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia ; Department of Oncology, Olivia Newton John Cancer and Wellness Centre, Austin Hospital, Heidelberg, VIC, Australia.
Cancer Manag Res ; 7: 189-98, 2015.
Article em En | MEDLINE | ID: mdl-26150735
ABSTRACT
Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article